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Abstract: Ibuprofen is a common over-the-counter drug taken for pain relief. However, recent studies
have raised concerns about its potential toxic effect with coronavirus disease 2019 (COVID-19), which
is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has been proposed
that ibuprofen may increase levels of angiotensin-converting enzyme 2 (ACE2), the human receptor
for SARS-CoV-2 infection. Therefore, paracetamol is suggested as an alternative to ibuprofen for
treating COVID-19 symptoms. Nevertheless, the relationship between intake of paracetamol or
ibuprofen and either susceptibility to infection by SARS-CoV-2 or modulation of cellular ACE2 levels
remains unclear. In this study, we combined data from human medical records and cells in culture
to explore the role of the intake of these drugs in COVID-19. Although ibuprofen did not influence
COVID-19 infectivity or ACE2 levels, paracetamol intake was associated with a lower occurrence of
COVID-19 in our cohort. We also found that paracetamol led to decreased ACE2 protein levels in
cultured cells. Our work identifies a putative protective effect of paracetamol against SARS-CoV-
2 infection. Future work should explore the molecular mechanisms underlying the relationship
between paracetamol and COVID-19.
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1. Introduction
Due to their analgesic and antipyretic properties, ibuprofen [(2RS)-1[4-(2-methyl
propyl) phenyl] propionic acid (BP. 2004)] and paracetamol (also known as acetaminophen
or N-acetyl-para-aminophenol) are the most frequently used over-the-counter drugs to
relieve pain [1–3]. However, these drugs show different adverse effects. Ibuprofen has
been shown to affect the gastrointestinal and cardiac systems while paracetamol is often
used as an alternative for patients with issues in these systems [3]. Accordingly, these
drugs are being used in treatment for coronavirus disease 2019 (COVID-19), a disease
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus
can be transmitted via several routes, including respiratory droplets, direct contact with
contaminated surfaces, and faecal–oral transmission [4]. The molecular mechanisms that
allow the entry of SARS-CoV-2 into human cells include binding of the viral spike (S)
protein to the human receptor angiotensin-converting enzyme 2 (ACE2) and S cleavage
by the host transmembrane protease serine 2 (TMPRSS2) [4,5]. ACE2, together with its
homologue ACE, regulates the renin–angiotensin–aldosterone system, which is involved
in regulating blood pressure and electrolyte homeostasis. Angiotensinogen is produced
in the liver and cleaved by renin, forming angiotensin I (Ang I). Ang I is then converted
to angiotensin II (Ang II) by ACE, and ACE2 cleaves Ang II to angiotensin (1–7). Ang II
has vasoconstrictive, pro-inflammatory, and pro-oxidative effects, whereas angiotensin
1–7 elicit vasodilating, anti-inflammatory, and antioxidant responses [6,7].
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Circa March 2020, French authorities reported the possibility of negative effects of
ibuprofen in COVID-19 patients through the modulation of ACE2 levels [8–10]. The con-
cern was based on findings that patients with hypertension and diabetes mellitus were
at an increased risk of COVID-19, possibly due to treatment with ACE inhibitors and
angiotensin II type I receptor blockers, which leads to increased levels of ACE2 [11]. Addi-
tionally, ibuprofen reportedly increased ACE2 levels in a rat model of type 1 diabetes [9,12].
Therefore, paracetamol has been suggested as an alternative to ibuprofen for treating pain
and high temperature in patients with COVID-19 [8,10].
Although a few studies have shown that ibuprofen intake does not worsen the clinical
outcome of COVID-19 [13], it remains unknown whether ibuprofen and paracetamol
influence SARS-CoV-2 infectivity. Moreover, despite ibuprofen-induced increases in ACE2
in rats [12], no human study has assessed whether ibuprofen or paracetamol affects levels
of ACE2. The aims of this study are, first, to assess if ibuprofen or paracetamol affect
SARS-CoV-2 infectivity, and second, to determine if they modulate ACE2 levels. Using
an analysis of half a million individuals that are part of the UK Biobank cohort, we show
that those recorded as taking paracetamol, but not ibuprofen, had a lower risk of testing
positive for SARS-CoV-2. We also found that treating human Caco-2 cells with paracetamol
decreased ACE2 protein levels.
2. Materials and Methods
2.1. UK Biobank Data Sources
The UK Biobank contains health data from over 500,000 community volunteers based
in England, Scotland, and Wales. Information about the geographical regions, recruitment,
and other characteristics has been previously reported [14]. Briefly, between 2006 and
2010, adults aged between 40 and 69 years were invited to participate, and extensive
demographic, lifestyle, clinical, and radiological information was collected. Baseline
assessments included a comprehensive series of questionnaires, face-to-face interviews,
physical examinations, and blood sampling, with links to electronic medical records.
Clinical data for dementia and other comorbidities were cross validated by an algorithm
from the UK Biobank, which considered UK Biobank baseline assessment data (verbal
interview), linked hospital admissions data, and death register data.
Data regarding medications are recorded as indicated in Resource 100235 of the UK
Biobank. In brief, by using a touchscreen questionnaire under the guidance of a UK Biobank
interviewer, the participants reported whether they regularly took any over-the-counter
or prescription medications. As regularity was defined as more frequently than every
3 months, short-term medication was excluded. We did not include information on the
dosage of each medication since these data were not available.
The method of linking COVID-19 results to UK Biobank participants has been pre-
viously published [15]. Briefly, Public Health England’s Second-Generation Surveillance
System is a centralised microbiology database covering English clinical diagnostics labora-
tories that provides national surveillance of legally notifiable infections, bacterial isolations,
and antimicrobial resistance. Public Health England issues a regular feed of COVID-19 test
results to the UK Biobank using a secure dynamic linkage algorithm.
Ethical approval from the UK Biobank was granted from the North West Multi-
Centre Research Ethics Committee. The current analysis was approved under UK Biobank
application #60124. A detailed list of variables evaluated in the present study is presented
in Table S1. We defined high blood pressure using the criterion of diastolic blood pressure
≥90 mmHg or systolic blood pressure ≥140 mmHg. Individual-level data were collected
from the UK Biobank on 5 February 2021.
2.2. Cell Culture and Drug Treatments
A549 cells were grown in Dulbecco’s modified Eagle medium (DMEM; Thermo Fisher
Scientific, Waltham, MA, USA, 41966) supplemented with 10% foetal bovine serum (FBS;
Merck, Kenilworth, NJ, USA, F9665); Calu-3 cells were grown in DMEM/F-12 medium
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(Thermo Fisher Scientific, Waltham, MA, USA, 11330-032) supplemented with 15% FBS and
Caco-2 cells in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA, A10491-
01) supplemented with 20% FBS. All cell media were supplemented with 1% penicillin and
streptomycin (Thermo Fisher Scientific, Waltham, MA, USA, 15070063). The cells were split,
and the media renewed every 2–3 days. The cells were seeded in 6-well plates at a density
of 175,000 (A549 and Caco-2) or 400,000 (Calu-3) cells per well for 24 h and then treated or
lysed. Caco-2 cells were treated with paracetamol (Merck, Kenilworth, NJ, USA, P0300000)
(0.1, 0.5, 1, 2.5, and 5 mM) or ibuprofen (Merck, Kenilworth, NJ, USA, I4883) (0.05 mM,
0.25 mM, 0.5 mM, 1 mM, and 2 mM) for 24 h. Dimethylsulfoxide (DMSO; 0.02%, Merck,
Kenilworth, NJ, USA, 276855) was added as a control for ibuprofen. Drugs were directly
added to the cell media. All cells tested negative for mycoplasma. Cell lines were obtained
from Professor Anne Willis’s group. A549 cells are derived from human epithelial lung
carcinoma cells, Caco-2 cells are derived from human epithelial colorectal adenocarcinoma
cells, and Calu-3 are derived from human epithelial lung adenocarcinoma cells. The Caco-2
cell line was validated by STR genotyping while the other cells were not validated. Drug
concentrations were chosen based on previously published articles reporting changes in
processes in different cell lines and, when possible, specifically in Caco-2 cells, as follows:
paracetamol [16–20] and ibuprofen [21–25].
2.3. Protein Extraction and Western Blotting
Protein extracts from cells treated as described were prepared by lysing cells in RIPA
digestion solution [150 mM NaCl (Fisher Chemical, Waltham, MA, USA, S/3161/53), 1%
Triton X-100 (BDH, Poole, UK, 306324N), 0.5% sodium deoxycholate (Sigma, St. Louis, MI,
USA, D5670), 0.1% SDS (Sigma, St. Louis, MI, USA, 05030), 50 mM Tris pH = 7.5 (Fisher
BioReagents, BP152-1)] with 1× proteinase inhibitors cOmplete Mini, EDTA-free (Roche,
Basel, Switzerland, 11836170001), and benzonase solution (50 mM Tris pH = 8.0, 4 mM
MgSO4 (Scientific Laboratory Supplies, Nottingham, UK, CHE2456) and 1× benzonase
(EMD Millipore, Burlington, MA, USA, 70664)). Protein concentration was measured
using a Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA,
23227). All extracts were mixed with 4× LDS loading buffer. For sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE), equivalent amounts of proteins were re-
solved on a 4–12% Bis-Tris gel (Thermo Fisher Scientific, Waltham, MA, USA, NP0335BOX
and NP0336BOX). Proteins were then transferred to nitrocellulose membranes and the
membranes were blocked in Tris-buffered saline (TBS; 0.15 M NaCl and 10 mM Tris, pH
7.5) with Tween 20 (Sigma, St. Louis, MI, USA, P1379) (TBS-T) containing 5% (w/v) dried
non-fat skim milk (BD, 232100) for 1 h at room temperature and then probed with the pri-
mary antibody before being incubated with the appropriate IRDye-conjugated secondary
antibody donkey anti-mouse (LI-COR, Cambridge, UK, 926-32212, Lot: C91023-09) or don-
key anti-rabbit (LICOR, Cambridge, UK, 926-32213, Lot: C91112-09). Antibody complexes
were visualised using an Odyssey (LI-COR, Cambridge, UK,), and quantifications were
performed using Image Studio Lite version 5.2.5 (LI-COR, Cambridge, UK,), with normali-
sation to the respective loading control (tubulin). Mouse monoclonal anti-α-tubulin (Merck,
Kenilworth, NJ, USA, T6074, RRDI: AB_477582, clone number: B-5-1-2, lot: 034M4837)
and rabbit monoclonal anti-ACE2 (Abcam, ab108252, RRDI: AB_10864415, clone number:
EPR4435(2), lot: GR3344245-2) antibodies were used. Both primary antibodies were used
at 1:1000 dilution and secondary antibodies at 1:20,000 dilution. Antibody validation can
be found on the companies’ websites as well as the references for these validations.
2.4. RNA Extraction and Quantitative Real-Time PCR
After 24 h of drug treatment, cells were washed 1× with phosphate-buffered saline
(PBS), trypsinised and centrifuged for 5 min at 500× g. The trypsin was removed, and
total RNA was extracted using TRIzol (Life Technologies, Carlsbad, CA, USA, 15596018)
and quantified by spectrophotometric analysis using a NanoDrop 2000 Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA,). Quantitative real-time PCR with reverse
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transcription (qRT-PCR) was performed using a real-time 7500 Fast Real-Time PCR System
(Applied Biosystems, Waltham, MA, USA) with a SensiFAST SYBR Lo-ROX One-Step Kit
(Bioline, London, UK, BIO-74005). Fold change was calculated using the comparative
CT method [26]. For qRT-PCR, we measured the coefficient of variation (CV) of the
technical replicates and excluded from statistical analysis samples with a CV over 3%.
Gene-specific primers were obtained from Sigma, St. Louis, MI, USA: ACE2—forward,
5′-CGAAGCCGAAGACCTGTTCTA-3′ and 5′-CAAGAGCAAACGGTTGAACAC-3′, and
reverse, 5′-GGGCAAGTGTGGACTGTTCC-3′ and 5′-CCAGAGCCTCTCATTGTAGTCT-
3′ [27]; GAPDH—forward, 5′-CTGACTTCAACAGCGACACC-3′, and reverse, 5′-TAGCCA
AATTCGTTGTCATACC-3′). GAPDH was used as a housekeeping gene.
2.5. Statistical Analysis
For the UK Biobank analysis (Figure 1), we first employed an exploratory approach to
identify which putative comorbidities influence the risk of testing positive for SARS-CoV-2.
We obtained a list of 18 variables (Table S1) based on 3 publications that explored risk
factors influencing SARS-CoV-2 infection [28–30]. We then applied an iterative variable
selection procedure combining unsupervised stepwise forward and stepwise backward
regression analyses to select the most suitable predictor or combination of predictors in
our models based on the Akaike information criterion. We calculated the proportional
odds and their 95% confidence intervals based on the coefficients of the binomial models
to quantify the effects of paracetamol and ibuprofen intake on the risk of testing positive
for SARS-CoV-2 [31]. The UK Biobank analysis was performed in R version 4.0.0 [32]
and Python version 3.7 in Jupyter Notebook version 5.5 [33]. The analysis source code,
detailed quality checks, and all supplementary material are available on GitHub (https:
//github.com/M1gus/NSAIDs_Ace2) (Accessed on 12 August 2021).
For Figure 2, the Kruskal–Wallis test with correction using Dunn’s multiple compari-
son test was utilised to test for significance, as the data did not follow a normal distribution
based on the Shapiro–Wilk test. For samples treated with drugs (Figures 3 and 4), samples
were normalised to their respective control and found to be normally distributed based
on the Shapiro–Wilk test. We performed a one-sample t-test followed by a correction to
control for the false discovery rate (FDR) using the two-stage step-up method of Benjamin,
Krieger, and Yekutieli at a 5%. Analyses of the mRNA and protein levels were done in
GraphPad Prism 9.0 (GraphPad Software, San Diego, CA, USA). Statistical significance
was defined as a p value or corrected p value ≤ 0.05. ** p < 0.01, * p < 0.05.




Figure 1. Paracetamol intake is associated with a lower risk of SARS-CoV-2 infection. (A) Workflow 
of the analysis. (B) Descriptive statistics of the cohort analysed relative to whether SARS-CoV-2 in-
fection occurred. For continuous variables such as age, the average age and standard deviation are 
shown; for discrete variables such as sex, the corresponding number of UK Biobank participants 
and their percentage relative to the total cohort are indicated. 
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Figure 2. Paracetamol intake is associated with a lower risk of SARS-CoV-2 infection. (A) Relation-
ship between paracetamol intake and SARS-CoV-2 infection. The numeric values of the odds ratios 
are shown in Table S2. (B) Relationship between ibuprofen intake and SARS-CoV-2 infection. The 
numeric values of the odds ratios are shown in Table S3. For both figures, the odds ratios calculated 
from logistic regressions and their respective 95% confidence intervals of the relationship, as well 
as covariates, are provided in Supplementary Tables. Statistically significant (p value ≤ 0.05) covari-
ates are shown in red and non-significant (p value > 0.05) covariates in grey. 
 
Figure 3. Levels of ACE2 in A549, Caco-2, and Calu-3 cell lines. Quantification of ACE2 protein 
levels normalised to tubulin in A549, Caco-2, and Calu-3 cell lines. Descriptive statistics (mean and 
standard error of the mean, s.e.m.) are shown to the right of the individual values for each data set. 
Three biologically independent samples were used per cell line. Significance is shown with an as-
terisk and red; non-significant p values are also shown (the Kruskal–Wallis test with correction us-
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and non-significant (p value > 0.05) covariates in grey.
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Figure 4. Paracetamol and ibuprofen do not influence ACE2 mRNA levels in Caco-2 cells. Quantifi-
cation of ACE2 mRNA levels in Caco-2 cells after treatment with (A) paracetamol or (B) ibuprofen 
for 24 h. Descriptive statistics (mean and s.e.m.) are shown to the right of the individual values for 
each data set. Four or five biologically independent samples were used per condition. Non-signifi-
cant corrected p values are shown (one-sample t-test with correction using the two-stage step-up 
method of Benjamin, Krieger, and Yekutieli for FDR correction at 5%). 
3. Results 
3.1. Regular Paracetamol Intake Results in a Lower Risk of SARS-CoV-2 Infection in the UK 
Biobank Cohort 
We used data from the UK Biobank cohort to explore the link between paracetamol 
and ibuprofen intake in SARS-CoV-2 infection. The UK Biobank is a biomedical database 
and research resource containing health records for more than half a million UK individ-
uals [34]. From 16 March 2020 to 1 February 2021, 60,446 of 502,505 UK Biobank partici-
pants were tested for SARS-CoV-2 (Figure 1A,B); of these, 14,877 were positive. To iden-
tify the factors influencing the risk of SARS-CoV-2 infection, we applied an iterative un-
supervised machine learning method based on several variables identified previously by 
us and others [28–30] (Table S1). We found that age, obesity (waist-to-hip ratio), sex, a 
previous history of cancer, diagnoses of dementia and chronic obstructive pulmonary dis-
order, ethnicity, deprivation (Townsend deprivation index), education, the number of 
people in the household, and house type had a significant association with a positive test. 
We therefore accounted for all these significant variables in all subsequent models. 
We next modelled whether previous intake of paracetamol modulates the risk of test-
ing positive for SARS-CoV-2 by using binomial regression and found that paracetamol 
led to a 6.63% reduction in the risk of infection (odds ratio, OR 0.93; 95% confidence inter-
val (CI) 0.91 to 0.96, p value = 0.004) (Figure 2A and Table S2). We applied the same method 
to assess whether ibuprofen also affects the risk of SARS-CoV-2 infection. Although we 
found that previous intake of ibuprofen was associated with a 2.98% decrease in the risk 
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Figure 4. Paracetamol and ibuprofen do not influence ACE2 mRNA levels in Caco-2 cells. Quantifica-
tion of ACE2 mRNA levels in Caco-2 cells after treatment with ( ) paracetamol or (B) ibuprofen for
24 h. Descriptive statistics (mean and s.e.m.) are shown to the right of the individual values for each
data set. Four or five biologically independent samples were used per condition. Non-significant
corrected p values are shown (one-sample t-test with correction using the two-stage step-up method
of Benjamin, Krieger, and Yekutieli for FDR correction at 5%).
3. Results
3.1. Regular Paracetamol Intake Results in a Lower Risk of SARS-CoV-2 Infection in the UK
Biobank Cohort
We used data from the UK Biobank cohort to explore the link between paracetamol and
ibuprofen intake in SARS-CoV-2 infection. The UK Biobank is a biomedical database and
research resource containing health records for more than half a million UK individuals [34].
From 16 March 2020 to 1 February 2021, 60,446 of 502,505 UK Biobank participants were
tested for SARS-CoV-2 (Figure 1A,B); of these, 14,877 were positive. To identify the factors
influencing the risk of SARS-CoV-2 infection, we applied an iterative unsupervised machine
learning method based on several variables identified previously by us and others [28–30]
(Table S1). We found that age, obesity (waist-to-hip ratio), sex, a previous history of cancer,
diagnoses of dementia and chronic obstructive pulmonary disorder, ethnicity, deprivation
(Townsend deprivation index), education, the number of people in the household, and
house type had a significant association with a positive test. We therefore accounted for all
these significant variables in all subsequent models.
We next modelled whether previous intake of paracetamol modulates the risk of
testing positive for SARS-CoV-2 by using binomial regression and found that paracetamol
led to a 6.63% reduction in the risk of infection (odds ratio, OR 0.93; 95% confidence interval
(CI) 0.91 to 0.96, p value = 0.004) (Figure 2A and Table S2). We applied the same method
to assess whether ibuprofen also affects the risk of SARS-CoV-2 infection. Although we
found that previous intake of ibuprofen was associated with a 2.98% decrease in the risk of
infection (Figure 2B and Table S3), this association was not significant (OR 0.97; 95% CI
0.94 to 1.00, p value = 0.29). Taken together, paracetamol, but not ibuprofen, is associated
with a lower risk of SARS-CoV-2 infection.
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3.2. Paracetamol, but Not Ibuprofen, Decreases ACE2 Protein Levels
As SARS-CoV-2 uses ACE2 on the surface of human cells for infection [5], we examined
whether paracetamol alters the risk of infection by SARS-CoV-2 by modulating ACE2 levels.
Human Calu-3 and Caco-2 cell lines have been shown to be highly susceptible to infection
by SARS-CoV-2 pseudo-virus [5], though the levels of ACE2 in these cell lines have not
been reported. Thus, we began by analysing levels of ACE2 protein in these cells; the lung
adenocarcinoma cell line A549 was used as a control because it has been shown to be more
resistant to infection by SARS-CoV-2 pseudo-virus [5]. Overall, levels of ACE2 in Caco-2
(p value = 0.0190) and Calu-3 (p value = 0.5172, non-significant) cells were higher than
those in A549 cells (Figure 3). Therefore, we decided to use Caco-2 cells for our next set
of experiments.
Next, we treated Caco-2 cells with paracetamol (concentration range between 0.1 and
5 mM) or ibuprofen (concentration range between 0.05 and 2 mM) for 24 h and assessed
levels of ACE2 mRNA and protein by real-time qPCR and Western blotting, respectively.
While levels of ACE2 mRNA were not significantly changed in both paracetamol- and
ibuprofen-treated cells, there was a tendency for decrease in ACE2 mRNA upon treatment
with 0.1 and 2.5 mM of paracetamol (corrected p values for both concentrations = 0.08)
(Figure 4A and Table S4), whereas no differences were observed after treatment with
ibuprofen (Figure 4B and Table S4).
Similarly, protein levels of ACE2 were significantly decreased with 0.1 mM, 0.5 mM,
1 mM, and 2.5 mM of paracetamol treatment (Figure 5A and Table S5), with no signif-
icant differences with 5 mM of paracetamol nor ibuprofen within the tested range of
concentrations (Figure 5B, Table S5).




Figure 5. Paracetamol decreases ACE2 protein levels in Caco-2 cells. Quantification of ACE2 protein 
levels in Caco-2 cells after treatment with (A) paracetamol or (B) ibuprofen for 24 h. Descriptive 
statistics (mean and s.e.m.) are shown to the right of the individual values for each data set. Four 
biologically independent samples were used per condition. Representative cropped immunoblots 
are shown and the whole immunoblots can be found in Figures S1 and S2. Significance is shown 
with asterisks and red; non-significant corrected p values are also shown (one-sample t-test with 
correction using the two-stage step-up method of Benjamin, Krieger, and Yekutieli for FDR correc-
tion at 5%). 
4. Discussion 
The effect of ibuprofen intake and SARS-CoV-2 infection remains unclear and con-
troversial [9,20,35–37]. Additionally, the association between paracetamol, another com-
monly used over-the-counter pain reliver, and COVID-19 has not been explored. In this 
study, we combined data from human medical records and in vitro results to investigate 
the relationship between ibuprofen, paracetamol, and SARS-CoV-2 infection as well as the 
possible mechanism. We showed that although ibuprofen does not affect SARS-CoV-2 in-
fection in our models, paracetamol is associated with a 6.63% reduction in infection risk. 
Additionally, we found that the protein levels of ACE2 were decreased in human Caco-2 
cells cultured with 0.1 mM, 0.5 mM, 1 mM, and 2.5 mM of paracetamol, while mRNA 
levels were not significantly changed. Therefore, our data suggest that paracetamol could 
affect ACE2 protein levels by mechanisms other than alterations in its translation (e.g., 
protein degradation). Since SARS-CoV-2 enters human cells by binding to ACE2 [5], the 
















0 [in mM]0.1 0.5 1 2.5 5
























































** ** ** **
Figure 5. Paracetamol decreases ACE2 protein levels in Caco-2 cells. Quantification of ACE2 protein
levels in Caco-2 cells after treatment with (A) paracetamol or (B) ibuprofen for 24 h. Descriptive
statistics (mean and s.e.m.) are shown to the right of the individual values for each data set. Four
biologically independent samples were used per condition. Representative cropped immunoblots are
shown and the whole immunoblots can be found in Figures S1 and S2. Significance is shown with
asterisks and red; non-significant corrected p values are also shown (one-sample t-test with correction
using the two-stage step-up method of Benjamin, Krieger, and Yekutieli for FDR correction at 5%).
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4. Discussion
The effect of ibuprofen intake and SARS-CoV-2 infection remains unclear and contro-
versial [9,20,35–37]. Additionally, the association between paracetamol, another commonly
used over-the-counter pain reliver, and COVID-19 has not been explored. In this study,
we combined data from human medical records and in vitro results to investigate the
relationship between ibuprofen, paracetamol, and SARS-CoV-2 infection as well as the
possible mechanism. We showed that although ibuprofen does not affect SARS-CoV-2
infection in our models, paracetamol is associated with a 6.63% reduction in infection risk.
Additionally, we found that the protein levels of ACE2 were decreased in human Caco-2
cells cultured with 0.1 mM, 0.5 mM, 1 mM, and 2.5 mM of paracetamol, while mRNA levels
were not significantly changed. Therefore, our data suggest that paracetamol could affect
ACE2 protein levels by mechanisms other than alterations in its translation (e.g., protein
degradation). Since SARS-CoV-2 enters human cells by binding to ACE2 [5], the decreased
levels of ACE2 caused by paracetamol may explain the lower risk of COVID-19 infectivity
observed in our model.
Overall, we observed significant variability in ACE2 mRNA levels in cells treated with
either paracetamol or ibuprofen (Figure 3). Furthermore, it is unclear why we detected
a non-significant decrease in levels of ACE2 in cells treated with 0.1 mM or 2.5 mM
paracetamol but not with other dosing regimens (0.5 mM, 1 mM, or 5 mM). In rat hearts,
levels of ACE2 mRNA exhibit circadian oscillation [38]. Hence, as we did not account for
daily rhythms as a factor in our analysis, it is possible that daily variations in levels of
ACE2 in Caco-2 cells account for the variability we observed.
A bulletin published by the UK Commission on Human Medicines and two other
studies found no clear evidence that acute use of ibuprofen increases the risk of developing
COVID-19 [8,13,39]. Similarly, we did not find evidence that ibuprofen intake alters the
risk of SARS-CoV-2 infection or ACE2 levels. Moreover, the data for the regular intake of
paracetamol or ibuprofen in UK Biobank participants pre-date the COVID-19 pandemic.
Our results suggest that regular uptake of any of these agents possibly modulates ACE2
levels, but experimental validation is required, particularly in animal models. Long-term
exposure to paracetamol has been reported to cause epigenetic changes in genes associated
with neural development [40], and it is thus important to determine whether the long-
term effects of paracetamol on ACE2 have an epigenetic component. Additionally, data
regarding the intake of paracetamol by participants during SARS-CoV-2 infection are not
available, precluding any conclusion regarding whether the protective effect of paracetamol
is due to its intake during viral infection. Although we did not explore the exact molecular
pathway by which paracetamol affects SARS-CoV-2 infection, there are several mechanisms
that could be behind this, including the ability of paracetamol to reduce the activity of
sirtuin 1 [41], a direct activator of ACE2 transcription [42]. Further studies are required to
elucidate the mechanisms by which paracetamol alters ACE2 levels.
Additionally, the epidemiological data set analysed in our study has several limitations.
Due to the retrospective nature of our methodology, case–control clinical studies are
required to elucidate the effect of paracetamol on COVID-19 pathology. Our cohort is
predominantly of white ethnicity, which limits the interpretability of our results for people
of other ethnicities. Due to limited information from the UK Biobank, we cannot explain
the reasons behind the regular uptake of paracetamol or ibuprofen in the participants
analysed in our study. Additionally, the duration and dosage of paracetamol or ibuprofen
are currently unavailable. COVID-19 deaths are connected with failure in the pulmonary
system, such as pneumonia and respiratory failure [43]. However, the Caco-2 cells used in
this study are derived from colorectal adenocarcinoma cells and the effect of paracetamol
or ibuprofen in ACE2 levels might be different in lung/alveolar cells. Finally, we cannot
exclude that the effect of these drugs on ACE2 levels may be altered during infection or in
a diseased individual.
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5. Conclusions
In this study, we showed that paracetamol is associated with a lower risk of COVID-19
infectivity and a decrease in ACE2 protein levels, while we found no association between
ibuprofen and COVID-19 infection.
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Paracetamol intake is associated with a decreased risk of COVID-19 infection; Table S3: Ibuprofen
intake does not affect the risk of SARS-CoV-2 infection; Table S4. Individual p values and corrected
FDR-corrected p values of Figure 3; Table S5. Individual p values and FDR-corrected p values of
Figure 4.
Author Contributions: N.S.L., G.F. and L.M.M. conceived of the original idea. Y.Y. developed and
performed the computational modelling. N.S.L. carried out the experimental work with the help
of Y.C. and G.F. N.S.L., Y.Y. and L.M.M. wrote the manuscript with the support of Y.C. and G.F. All
authors provided critical feedback and approved the final version of the manuscript.
Funding: This study was funded by the UK Medical Research Council, intramural project MC_UU_
00025/3 (RG94521).
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki. UK Biobank ethical approval was granted from the North West Multi-
Centre Research Ethics Committee. The current analysis was approved under UK Biobank applica-
tion #60124.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the
study by the UK Biobank.
Data Availability Statement: Access to the UK Biobank data can be applied for via the official UK
Biobank website (https://www.ukbiobank.ac.uk/) (Accessed on 5 February 2021). All other analyses
can be found in our GitHub repository (https://github.com/M1gus/NSAIDs_Ace2) (Accessed on
12 August 2021).
Acknowledgments: We would like to thank A. Willis, G. Garland, and R. Harvey for sharing
the cell lines. This study was funded by the UK Medical Research Council, intramural project
MC_UU_00025/3 (RG94521).




ACE2 angiotensin-converting enzyme 2
Ang I angiotensin I
Ang II angiotensin II
CI confidence interval
COVID-19 coronavirus disease 2019
COX-1 cyclooxygenase-1
COX-2 cyclooxygenase-2
FBS foetal bovine serum
mRNA messenger RNA
NSAIDs non-steroid anti-inflammatory drugs
OR odds ratio
qRT-PCR quantitative real-time PCR with reverse transcription
S spike
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
s.e.m. standard error of the mean
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